

Book of OHDSI 2.0: How Do We Get There?

OHDSI Community Call March 11, 2025 • 11 am ET

n ohdsi



Upcoming Community Calls

| Date | Topic |
|---------|--|
| Mar. 4 | Vocabulary Release Update, Winter 2025 |
| Mar. 11 | Book of OHDSI 2.0 Brainstorm and Planning Session |
| Mar. 18 | OHDSI Evidence Network and Data Diagnostics Design |
| Mar. 25 | Methods for Evaluating Data Fitness for Use |
| Apr. 1 | Recent OHDSI Publications |







Three Stages of The Journey

Where Have We Been? Where Are We Now? Where Are We Going?









Congratulations to the team of ChulHyoung Park, So Hee Lee, Da Yun Lee, Seoyoon Choi, Seng Chan You, Ja Young Jeon, Sang Jun Park, and Rae Woong Park on the publication of **Analysis of Retinal Thickness in Patients** With Chronic Diseases Using **Standardized Optical Coherence Tomography Data: Database Study Based** on the Radiology Common Data Model in JMIR Medical Informatics.



This work aims to demonstrate that by standardizing optical coherence tomography (OCT) data into an R-CDM format, multi-institutional collaborative studies analyzing changes in retinal thickness in

patients with long-standing chronic diseases can be performed efficiently.







Congratulations to the team of Inessa Cohen, Zihan Diao, Pawan Goyal, Aarti Gupta, Kathryn Hawk, Bill Malcom, Caitlin Malicki, Dhruv Sharma, Brian Sweeney, Scott Weiner, Arjun Venkatesh and Andrew Taylor on the publication of Mapping Emergency Medicine Data to the **Observational Medical Outcomes Partnership Common Data Model: A Gap Analysis of the American College of Emergency Physicians** Clinical Emergency Data Registry in the Journal of the American College of Emergency Physicians Open.



BRIEF REPORT

The Practice of Emergency Medicine



Mapping Emergency Medicine Data to the Observational Medical Outcomes Partnership Common Data Model: A Gap Analysis of the American College of Emergency Physicians Clinical Emergency Data Registry

Inessa Cohen MPH^{1,2,3} , Zihan Diao AB¹, Pawan Goyal MD, MHA⁴, Aarti Gupta MBBS⁴, Kathryn Hawk MD, MHS¹, Bill Malcom PMP⁴, Caitlin Malicki MPH¹, Dhruv Sharma MS⁴, Brian Sweeney⁴, Scott G. Weiner MD, MPH⁵, Arjun Venkatesh MD, MBA^{1,6}, R. Andrew Taylor MD, MHS^{1,2}

¹Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, USA

Correspondence

R. Andrew Taylor, MD, MHS, Department of Emergency Medicine, Yale School of Medicine, New Haven, 464 Congress Ave. Suite 260, New Haven, CT 06519, USA. Email:

Abstrac

Objectives: This study aims to conduct a gap analysis to determine the feasibility of mapping electronic health record data from the Clinical Emergency Data Registry (CEDR) to the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM).





²Section for Biomedical Informatics and Data Science, Yale University School of Medicine, New Haven, Connecticut, USA

³Program of Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut, USA

⁴American College of Emergency Physicians, Washington, DC, USA

Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA

⁶Center for Outcomes Research and Evaluation (CORE), Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut. USA





Congratulations to the team of Seonji Kim, Subin Kim, Chungsoo Kim, Junhyuk Chang, Rae Woong Park, Kyung Won Kim, and Seng Chan You on the publication of **Utility of Treatment Pattern Analysis Using a Common Data** Model: A Scoping Review in Healthcare Informatics Research.

Review Article

Healthc Inform Res. 2025 January;31(1):4-15. https://doi.org/10.4258/hir.2025.31.1.4 pISSN 2093-3681 • eISSN 2093-369X



Utility of Treatment Pattern Analysis Using a Common Data Model: A Scoping Review

Eun-Gee Park¹, Min Jung Kim², Jinseo Kim¹, Kichul Shin², Borim Ryu¹

¹Center for Data Science, Biomedical Research Institute, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea ²Division of Rheumatology, Department of Internal Medicine, Seoul, Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea

Objectives: We aimed to derive observational research evidence on treatment patterns through a scoping review of common data model (CDM)-based publications. Methods: We searched the medical literature databases PubMed and EMBASE, as well as the Observational Health Data Sciences and Informatics (OHDSI) website, for papers published between January 1, 2010 and August 21, 2023 to identify research papers relevant to our topic. Results: Eighteen articles satisfied the inclusion criteria for this scoping review. We summarized study characteristics such as phenotypes, patient numbers, data periods, countries, Observational Medical Outcomes Partnership (OMOP) CDM databases, and definitions of index date and target cohort. Type 2 diabetes mellitus emerged as the most frequently studied disease, covered in five articles, followed by hypertension and depression, each addressed in four articles. Biguanides, with metformin as the primary drug, were the most commonly prescribed first-line treatments for type 2 diabetes mellitus. Most studies utilized sunburst plots to visualize treatment patterns, whereas two studies used Sankey plots. Various software tools were employed for treatment pattern analysis, including JavaScript, the open-source ATLAS by OHDSI, R code, and the R package "TreatmentPatterns." Conclusions: This study provides a comprehensive overview of research on treatment patterns using the CDM, highlighting the growing importance of OMOP CDM in enabling multinational observational network studies and advancing collaborative research in this field.

Keywords: Epidemiologic Methods, Cohort Studies, Drug Utilization, Scoping Review, Common Data Elements









Congratulations to the team of Yi Chai, Ivan Lam, Kenneth Man, Joseph Hayes, Eric Wan, Xue Li, Celine Chui, Wallis Lau, Xiaoyu Lin, Can Yin, Min Fan, Esther Chan, Ian Wong & Hao Luo on the publication of **Psychiatric** and neuropsychiatric sequelae of COVID-19 within 2 years: a multinational cohort study in BMC Medicine.

RESEARCH Open Access



Psychiatric and neuropsychiatric sequelae of COVID-19 within 2 years: a multinational cohort study

Yi Chai^{1,2,3†}, Ivan C. H. Lam^{2†}, Kenneth K. C. Man^{2,4,5}, Joseph F. Hayes^{6,7}, Eric Y. F. Wan^{2,5,8}, Xue Li^{2,5,9}, Celine S. L. Chui^{5,10,11}, Wallis C. Y. Lau^{2,4,5}, Xiaoyu Lin¹², Can Yin¹², Min Fan², Esther W. Chan^{2,5,13}, Ian C. K. Wong^{2,14} and Hao Luo^{15*}

bstract

Background The long-term psychiatric and neuropsychiatric sequelae of COVID-19 across diverse populations remain not fully understood. This cohort study aims to investigate the short-, medium-, and long-term risks of psychiatric and neuropsychiatric disorders following COVID-19 infection in five countries.

Methods This population-based multinational network study used electronic medical records from France, Italy, Germany, and the UK and claims data from the USA. The initial target and comparator cohorts were identified using an exact matching approach based on age and sex. Individuals diagnosed with COVID-19 or those with a positive SARS-CoV-2 screening test between December 1, 2019, and December 1, 2020, were included as targets. Up to ten comparators without COVID-19 for each target were selected using the propensity score matching approach. All individuals were followed from the index date until the end of continuous enrolment or the last healthcare encounter. Cox proportional hazard regression models were fitted to estimate the risk of incident diagnosis of depression, anxiety disorders, alcohol misuse or dependence, substance misuse or dependence, bipolar disorders, psychoses, personality disorders, self-harm and suicide, sleep disorders, dementia, and neurodevelopmental disorders within the first 6 months (short-term), 6 months to 1 year (medium-term), and 1 to 2 years (long-term) post-infection.

Results A total of 303,251 individuals with COVID-19 and 22,108,925 individuals without COVID-19 from five countries were originally included. Within the first 6 months, individuals with COVID-19 had a significantly higher risk of any studied disorders in all databases, with Hazard Ratios (HRs) ranging from 1.14 (95% CI, 1.07–1.22) in Germany to 1.89 (1.64–2.17) in Italy. Increased risks were consistently observed for depression, anxiety disorders, and sleep disorders across almost all countries. During the medium- and long-term periods, higher risks were observed only for depression (medium-term: 1.29, 1.18–1.41; long-term: 1.36, 1.25–1.47), anxiety disorders (medium-term: 1.29, 1.20–1.38; long-term: 1.37, 1.29–1.47), and sleep disorders (medium-term: 1.10, 1.01–1.21; long-term: 1.14, 1.05–1.24) in France, and dementia (medium-term: 1.65, 1.28–2.10) in the UK.





Three Stages of The Journey

Where Have We Been? Where Are We Now? Where Are We Going?







Upcoming Workgroup Calls




| Date | Time (ET) | Meeting |
|-----------|-----------|--------------------------------------|
| Tuesday | 12 pm | Generative AI and Analytics |
| Tuesday | 12 pm | Atlas |
| Tuesday | 3 pm | OMOP CDM Oncology Outreach/Research |
| Wednesday | 9 am | Patient-Level Prediction |
| Wednesday | 2 pm | Natural Language Processing |
| Wednesday | 7 pm | Eyecare and Vision Research |
| Thursday | 9:30 am | Network Data Quality |
| Thursday | 10:30 am | Evidence Network |
| Thursday | 12 pm | Strategus |
| Thursday | 7 pm | Dentistry |
| Friday | 9 am | Phenotype Development and Evaluation |
| Friday | 10 am | GIS - Geographic Information System |
| Friday | 11 am | Clinical Trials |
| Friday | 11:30 am | Steering |
| Friday | 11 pm | China Chapter |
| Monday | 10 am | Getting Started Subgroup |
| Monday | 10 am | Africa Chapter |
| Monday | 11 am | Data Bricks User Group |
| Monday | 2 pm | Electronic Animal Health Records |



Industy WG Studyathon Questionnaire

The Industry WG is hosting an industry specific studaython (potential dates are May or June) and is looking for input on who might be interested and what dates work best.

If you are a member of the Industry WG or are considering joining the team, please fill out this survey by the end of this week.





OHDSI Europe Symposium - Save-the-date!





Save-the-date

5-7 July 2025

Location

Old Prison - Hasselt
University
Martelarenlaan
Hasselt - BELGIUM





Global Symposium: Oct. 7-9

The 2025 OHDSI Global Symposium will return to the Hyatt Regency Hotel in New Brunswick, N.J., on Oct. 7-9.

The first Scientific Review Committee meeting will be held Thursday at 11 am.





The Center for Advanced Healthcare Research Informatics (CAHRI) at Tufts Medicine welcomes:



Hongfang Liu, PhD

D. Bradley McWilliams Chair Professor of Biomedical Informatics, Vice President of Learning Health System, University of Texas Health Science Center at Houston

'A Translational Science Framework in Advancing Healthcare AI'

March 27, 2025, 11am-12pm EST Virtually via Zoom





R/Medicine Conference

R/Medicine 2025



AN R CONSORTIUM VIRTUAL CONFERENCE

Call for Proposals

Submission is now open!

SUBMIT HERE

We are seeking abstracts for:

- Lightning talks (10 min, Thursday June 12 or Friday June 13) Must pre-record and be live on chat to answer questions
- Regular talks (20 min, Thursday June 12 or Friday June 13) Must pre-record and be live on chat to answer questions
- **Demos** (1 hour demo of an approach or a package, Tuesday June 10 or Wednesday June 11) Done live, preferably interactive
- Workshops (2-3 hours on a topic, Tuesday June 10 or Wednesday June 11) Detailed instruction on a topic, usually with a website and a repo, participants can choose to code along, include 5-10 min breaks each hour.

An abstract proposal should describe a presentation of methodology, a study or project, or an example or case study relevant to one (or more) of our fields of interest, with R-based tools having a substantial role in the work. The content of the presentation should be of interest to the R/Medicine community.

Dates to Remember

CFP Closes: Friday, April 11th at 11:59 PM EDT

CFP Notifications: Friday, April 25th

Schedule Announcement: Friday, May 9th

Pre-Recorded Video Submission: Monday, June 2nd



n ohds



Monday

Adopting the OMOP Oncology CDM at the Helsinki University Hospital

(Valtteri Nieminen, Alexey Ryzhenkov, Johanna Sanoja, Salma Rachidi, Juho Lähteenmaa, Joonas Laitinen, Samu Eränen, Tomi Mäkelä, **Eric Fey, Kimmo Porkka)**

Cancer Data and Adopting the OMOP Oncology extension at the Helsinki University Hospital (HUS)

A PRESENTER: Valtteri Nieminen

Observational oncology studies require specific data and clinical events to be aggregated to represent cancer. The OMOP Oncology extension provides a robust model for cancerspecific abstractions as part of the CDM.

Linking data representing clinical events on a patient's journey to form episodes and treatment regimens is challenging, Hospital IT systems are designed for routine care and administration. The source data models are often highly heterogenous and non-standard

Although challenging, implementing a highquality OMOP database for cancer research brings value for implementing more precise cancer care and conducting high-quality

1) Assembly of an interdisciplinary working group consisting of clinicians, data scientists. analysts, engineers and OMOP experts. 2) Defining a set of prioritized variables that would enable meaningful oncology studies 3) Finding best available source, together by a data-analyst and a clinical expert 4) Constructing source-to-concept mappings and an ETL plan iteratively together by the

5) Quality control (OC) in three stages:

- · Data-driven QC with automated pipeline (Data Quality Dashboard, tests)
- · Expert QC: plausibility evaluation by
- External benchmark data: validation against previous, hand-curated datasets

RESULTS

We have partially or completely adopted the OMOP Oncology extension for


- 1. Somatic mutation data
- 2. Treatment regimens

www.ohdsi.org

- 3. Cancer episodes and initial diagnoses
- 4. The cancer modifiers and primary diagnosis models

LUNG CANCER STUDY-A-THON 2025

March 2025 HUS will host an international study-a thon on lung cancer, sponsored by the iCAN project Interested data sites are welcome to join!




Adopting the OMOP Oncology CDM for hospitals is feasible and holds great promise for both clinicians and federated observational cancer studies at scale

> RESEARCH Example showcase of **LUNG CANCER** iCAN share

> > DATASET OF

treated Lung Cancer patients from 2018, with histology, stage, lines of treatment and clinical parameters

SUPPORTING CLINICIANS **OPEN SOURCE TOOLS**



DATA AT-A-GLIMPSE



including chemotherapy, IO, targeted and non-targeted. Radiotherapy mapping in

HISTOLOGY AND IMMUNOHISTOCHEMISTR



Biomarkers (for ex., PD-L1%) from indication specific pathologist's statement forms from biopsies and surgeries.

Regex-based extraction from

care team meeting notes. For example, available for -75% of





Mapping from semi-structured geneticist's statements and mutation panels, .vcf files to OMOP genomics.

all NSCLC patients

LABS &


operations widely mapped and

DIAGNOSES



Mapping in process from ICD-O-3 pathologist's statements where available. Where not,

Primary- and initial diagnosis for Oncology CDM episodes



Sanoja, Salma Rachidi, Juho Lähteenmaa, Joonas Laitinen, Samu Eränen, Johanna Niklander, Mikko Vaarala, Anna Kuosmanen, Oscar Brück, Pasi Rikala, Anna Virtanen, Marianna Niemi, Tom Mäkelä. Eric Fey. Kimmo Porkka







#JoinTheJourney



Tuesday

ETIng from your OMOP CDM to your OMOP CDM? An efficient solution to vocabulary migration

(Clair Blacketer, Anton Ivanov, **Evanette Burrows, Dmitry Dymshyts,** Frank DeFalco)

ETLing from your OMOP

An efficient solution to vocabulary migration and data quality enhancement

▲ PRESENTER: Clair Blacketer

- · Updating the vocabulary of an existing CDM instance usually necessitates a complete rerun of the ETL process.
- This is especially problematic when access to the native data is restricted.
- We present a novel ETL method that allows for vocabulary updates without reverting to the native data

ConceptID source code

| Comcept Code | Consept Name | Valid Dates | Happed Concept |
|-----------------|-----------------|------------------|-------------------|
| J9080 | Vincetalne | Velid until 2010 | 1082881 |
| J9080 | Teolistamate | Valid From 2020 | 261883 |

Data Quality Rules Applied



Implement logic to correct any data quality issues observed in original CDM.

Standard Concept Mapping & Movement









- · The primary focus of the ETL was the event tables, where most vocabulary mappings
- The re-mapped source codes from step 1 were converted to standard concepts and the corresponding event tables were populated based on the target concept
- This required all primary keys to be reissued.

Operationalize ETL Logic

. Developed code to operationalize

the CDM-to-CDM ETL logic. Transferred any custom vocabularies from the original

The DQD was used post generation of the new CDM instance with updated vocabulary to identify any errors or issues in the concept mappings.

The method was applied to IOVIA® Adjudicated Health Plan Data to update the vocabulary version from 31-Aug-2023 to 29-Feb-2024

You can keep your vocabulary up-to-date by ETLing your current CDM to a new CDM using our tool.






Take a picture to download the short report

RESULTS



to-CDM ETL specifications

- 13.556 persons without gender were removed
- 379,586 standard concepts were added to the OHDSI Vocabularies between versions 31-Aug-2023 and 29-Feb-2024



apped to new concepts between vocabulary versions 15-Aug-2003 and 29-Feb-2004, by table.

Number of Records that Moved tomeins, by Destination Table

Aug-2023 and 29-Feb-2024, by destination table

- Domain changes
- Multi-domain mappines Primary key re-issuance
- Database-specific vocabulary Integration
- Data Quality Dashboard
- Burrows*, Dmitry Dymstyts*, Frank DeFalco*

Janesen Research & Development, Raritse, NJ Department of Medical Informatics, Eraenus MC, Rotteedam, NL

Johnson&Johnson











Wednesday

Comparative Analysis of OMOP CDM Database Profiles Across Institutions and Future Research Implications

(Haeun Lee, Snehil Gupta, Clair Blacketer, Michael Cook, Shinji Naka, Ruochong Fan, Benjamin Martin, **Khyzer Aziz, Linying Zhang, Paul Nagy)** Comparative Analysis of OMOP CDM Database Profiles Across Institutions and Future Research Implications

A PRESENTER: Haeun Lee

- The OHDSI community has facilitated network studies through a federated approach, yet assessing institutional data attributes and suitability within this distributed framework remains challenging.
- Database profiles provide detailed insights into OMOP CDM databases, enabling the evaluation of data characterization and study eligibility for multicenter studies
- This study aims to examine Database profiles, assess data patterns, and explain their implications for future research within the OHDSI community.

METHODS


1 Data sources and Tools

Utilized DbDiagnostics (v1.3.1) to analyze OMOP CDM databases from Johns Hopkins School of Medicine and Washington University School of Medicine in St Louis


Generated summary statistics for various CDM domains and compared common concepts, data density, and data completeness between


3. Evaluation

Assessed data characterization and consistency to evaluate OMOP CDM implementation across



| Domain | Site A | Site B |
|----------------------|--------|--------|
| Person | Y | Y |
| Visit Occurrence | Y | Y |
| Condition Occurrence | Y | Y |
| Procedure Occurrence | Y | Y |
| Measurement | Y | Y |
| Drug Exposure | Y | Y |
| Observation | Y | Y |
| Care Site | N | Y |
| Device Exposure | Y | N |









- The study analyzed data from 2.1 M patients at Site A and 8 M patients at Site B, revealing data quality issues and gaps in demographic
- While both institutions used SNOMED CT codes for condition concepts, differences were observed in vocabularies for commo procedures and measurements.
- Essential data domains were present at both sites, though care site information was excluded from Site A's OMOP instance.
- Data density varied between Site A and Site B across overlapped domains with Site A generally showing higher densities except in

- Database profiles are crucial for understanding institutional characteristics and their ETL and mapping techniques
- Addressing variations between institutions is essential to improve data consistency and provide critical insights for evaluating study eligibility based on specific research questions
- Sharing database profiles enhances network studies through improved collaboration, and cross-institutional transparency.
- Haeun Lee, Snehil Gupta, Clair Blacketer Michael Cook, Shinji Naka, Ruochong Fan, Benjamin Martin, Khyzer Aziz, Linying Zhang, Paul Nagy



Washington University in St Louis







Thursday

Atlas2AoU: Enabling
Comparison of OHDSI
Phenotype Library
Phenomic Profiles in All
of Us and the UK
Biobank

(Abigail Newbury, Xinzhuo Jiang, Karthik Natarajan, Gamze Gürsoy)

Atlas2AoU:

Enabling Comparison of OHDSI Phenotype Library Phenomic Profiles in All of Us and the UK Biobank

♣ PRESENTER: Abigail Newbury


INTRO:

- Biobanks facilitate precision medicine efforts to improve understanding of disease etiology
- Biobanks are increasingly providing clinical data in OMOF CDM format, which allows researchers to use complex rule based phenotyping algorithms
- These complex phenotyping algorithms can result in more accurate patient cohorts
- Due to technical limitations in the All of Us (AoU) Researcher Workbench, direct application of OHDSI Phenotype Library (PL) phenotype algorithms (constructed by ATLAS) has been challenging
- We propose a tool Atlas2AoU to enable OHDSI PL cohort creation in the AoU workbench

METHODS

- Atlas2AoU modifies ATLAS
 queries by calling a temporary
 observation period table created
 by taking the minimum and
 maximum dates of recorded
 clinical events across 9 OMOP
 CDM tables
- We illustrate the use of Atlas2AoU by comparing the prevalence of 423 cohorts from the OHDSI Phenotype Library v3.1.6 between AoU and the UK Biobank (UKBB)
- We emphasize the importance of cross-biobank comparison by comparing geographic disease prevalence, demographics and social determinants of health (SDOH), and results of genomewide association studies (GWAS) between biobanks for Chronic Obstructive Pulmonary Disease (COPD).

Atlas2AoU gives researchers the ability to create ATLAS phenotypes in the All of Us Workbench which furthers precision medicine efforts & enables cross-biobank comparison




Impact of Atlas2AoU

| enotype | Original query false positives | Original query false negatives | Original query cohort size | Atlas2AoU query cohort size |
|---------|---|---|----------------------------------|-----------------------------------|
|) | 370 | 43,111 | 7,503 | 50,244 |
| PD | 488 | 23,044 | 2,256 | 24,812 |
| ite MI | 0 | 6.131 | 194 | 6.325 |


Atlas2AoU query modification leads to accurate cohorts and increases sample size

Prevalence comparison



AoU has significantly higher prevalence compared to the UKBB for 335 of the 423 OHDSI PL phenotypes

Detailed COPD comparison



- Significantly higher prevalence in AoU
 Regions of high prevalence: UKBB: West
- Regions of high prevalence: UKBB: West Dunbartonshire, Glasgow City, and West Lothian: AoU: Kansas and Missouri
- SDOH variables: Smoking pack years, companionship, income, alcohol frequency and education level significantly different among cohorts
- GWAS: variants in the exons of HYKK, CHRNA3, CHRNA4, and CHRNA significantly associated with COPD in the UKBB
- Abigail Newbury, Xinzhuo Jiang, Karthik Natarajan, Gamze Gürsoy









download the full



Friday

Measuring Severe
Maternal Morbidity: A
Pilot OHDSI Electronic
Health Record Network
Study

(Stephanie A. Leonard, Louisa H. Smith, Khyzer Aziz, Andreea Creanga, Elliott K. Main, Brian T. Bateman, Alison Callahan)

Measuring Severe Maternal Morbidity: A Pilot OHDSI Electronic Health Record Network Study

Stephanie A. Leonard, Louisa H. Smith, Khyzer Aziz, Andreea Creanga, Elliott K. Main, Brian T. Bateman, Alison Callahan

Introduction

Background

- The CDC established an index of "severe maternal morbidity" (SMM), which currently comprises 20 indicators and is widely used
- Validity concerns exist about the SMM Index.
 National SMM estimates are derived from ICD codes in claims data, which are limited by inconsistencies in data collection and accuracy, long delays in data availability, high costs, and compatibility issues across
- Prior work from the OHDSI community has shown how OHDSI approaches can mitigate some of these limitations, but the work has largely been conducted in claims databases

Study Aim: Our aim for this study was to develop an approach to use OMOP electronic health record (EHR) data from healthcare systems to improve the measurement of SMM that can then be implemented across a network

Methods

- 1. Created an ATLAS live birth cohort
- Validated the cohort definition using live birth record counts extracted from Stanford Medicine Epic Stork EHR data
- Cohort definition implemented at Johns Hopkins Medicine and MaineHealth, and compared with the number of live births reported by the healthcare systems to state health departments
- Created an ATLAS cohort definition for SMM, based on the CDC index, using Stanford EHR data
- Calculated SMM incidence and compared with Stanford hospitalization discharge data.
- 6. Reviewed random sets of cases to confirm SMM. We
- Modified the cohort definition accordingly based on these validation steps
- Generated record counts and calculated SMM incidence in all 3 healthcare systems using ATLAS

OHDSI network studies using EHR data sources to measure severe maternal morbidity are feasible and accurate




Figure. Severe maternal morbidity (percentage of live births) across OMOP electronic health record (EHR) datasets from three healthcare systems in the U.S. (In total: 1827 cases out of 102,488 births over 5.5 yr)









Paculte

- We successfully used ATLAS to generate SMM cohorts using OMOP EHR data from 3 healthcare systems
- Each system had 24,000-40,000 births (total N = 102,488 births)
- SMM incidence from January 1, 2019 to May 31, 2024 at Healthcare System A was 2.05%, at Healthcare System B was 1.41%, and at Healthcare System C was 1.74% (Flaure)
- Across the 3 systems, the live birth cohort definition captured 92-99% of live births as reported to state health departments and in Stork EMP data.
- The incidence of SMM using the cohor definition at Stanford was within 0.04 percentage points of the annual hospital reported incidence

Conclusion

- This pilot study generated evidence that supports the feasibility and accuracy of OHDSI network studies using EHR data sources to measure SMM
- Challenges unique to OMOP obstetric EHR data were identified and addressed
- Our approaches are informative for perinatal health OHDSI network studies and could facilitate an impactful addition to claims databases or aggregated multi-site FHR data
- Based on our results, we are expanding the study to a broad national network of healthcare systems with ATLAS and EHR data in the OMOP CDM
- Leveraging this network, we will evaluate how proposed modifications to the SMM Index would affect incidence and we will characterize patient cohorts identified under the proposed modified cohort definitions.

Author Affiliations

- Stanford University: SAL, EKM, BTB, AC
- Johns Hopkins University: KA, AC
- Northeastern University: LHS

OHDSI Workgroup

This work is part of the OHDSI Perinatal and Reproductive Health Group (PRHeG)

Contact **leonard@ohdsi.org** if you are interested in joining the workgroup and/or this network study





Where Are We Going?

Any other announcements of upcoming work, events, deadlines, etc?



Three Stages of The Journey

Where Have We Been? Where Are We Now? Where Are We Going?







The weekly OHDSI community call is held every Tuesday at 11 am ET.

Everybody is invited!

Links are sent out weekly and available at: ohdsi.org/community-calls-2025